- About us
- Clinical trials
- News & Publications
Our lead candidate, BOXR1030, uniquely combines the BOXR-discovered GOT2 transgene, a critical enzyme involved in cellular metabolism, with CAR T technology targeting GPC3-expressing tumors. BOXR1030 is a next generation CAR T cell therapy which benefits from its enhanced T cell metabolism in the solid tumor microenvironment.
SOTIO has demonstrated strong preclinical evidence in models that simulated the solid tumor microenvironment. In vitro, BOXR1030 T cells resisted suppressive tumor microenvironment-like conditions and improved T cell proliferation under both hypoxic and low glucose conditions compared with standard CAR T cells.
Multiple in vivo models with BOXR1030 demonstrated superior activity compared to standard CAR T cell therapies with treated animals achieving complete tumor regression. BOXR1030 cells were shown to be more resistant to dysfunction with fewer markers of exhaustion compared to the control CAR T cells isolated from the tumors of treated animals. In vivo models were intentionally designed to be stringent, mimicking the minimal efficacy of standard CAR T therapies today.
Initial indications for BOXR1030 include, hepatocellular carcinoma, squamous cell carcinoma of the lung.
BOXR1030 is expected to enter the clinic in the beginning of 2022. SOTIO’s in-house cell therapy manufacturing expertise and capabilities will facilitate the rapid and efficient scale up of the BOXR T cell therapy program.